Zymeworks Inc.

ZYME Healthcare Biotechnology

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.

25.07 0.68 −2.64%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
16.2×
Dividend yield
—
F-score
7/9
Altman Z
11.56
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
9.62 18.74 23.01 51.39
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(41.20) (193.53) (40.90) (59.72)
P/B ratio
4.04 7.39 11.43 23.74
EV/Sales
7.92 16.58 18.52 44.11
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(16.08) (49.69) (19.33) (13.49)
Current Ratio
6.94 5.88 10.82 6.32
Net Debt/EBITDA
12.90 5.42 8.24 6.74
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(4.92%) (4.10%) (5.47%) (7.73%)
Free Cash Flow Yield
(5.12%) (1.78%) (4.16%) (6.36%)
Free Cash Flow per Share
(0.42) (0.15) (0.62) (0.44)
Book value per Share
4.22 3.56 2.19 1.10
Free Cash Flow
(31.82) (10.98) (45.93) (31.95)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates